JNJ

188.37

-0.71%↓

ABT

128.3

+1.91%↑

MDT

94.2

+0.53%↑

VEEV

296.28

+0.2%↑

A

146.93

+0.09%↑

JNJ

188.37

-0.71%↓

ABT

128.3

+1.91%↑

MDT

94.2

+0.53%↑

VEEV

296.28

+0.2%↑

A

146.93

+0.09%↑

JNJ

188.37

-0.71%↓

ABT

128.3

+1.91%↑

MDT

94.2

+0.53%↑

VEEV

296.28

+0.2%↑

A

146.93

+0.09%↑

JNJ

188.37

-0.71%↓

ABT

128.3

+1.91%↑

MDT

94.2

+0.53%↑

VEEV

296.28

+0.2%↑

A

146.93

+0.09%↑

JNJ

188.37

-0.71%↓

ABT

128.3

+1.91%↑

MDT

94.2

+0.53%↑

VEEV

296.28

+0.2%↑

A

146.93

+0.09%↑

Search

BioMarin Pharmaceutical Inc

Открыт

СекторЗдравоохранение

54.75 -0.65

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

52.18

Макс.

56.37

Ключевые показатели

By Trading Economics

Доход

241M

426M

Продажи

80M

825M

P/E

Средняя по отрасли

15.701

37.461

Прибыль на акцию

1.44

Рентабельность продаж

51.637

Сотрудники

3,040

EBITDA

95M

319M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+70.97% upside

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-1.3B

10B

Предыдущая цена открытия

55.4

Предыдущая цена закрытия

54.75

Новостные настроения

By Acuity

42%

58%

139 / 373 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Very Strong Bearish Evidence

BioMarin Pharmaceutical Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

27 окт. 2025 г., 23:32 UTC

Приобретения, слияния, поглощения

CSL Delays Flu-Vaccine Spinoff, Cuts Guidance As U.S. Vaccination Rates Decline

27 окт. 2025 г., 23:00 UTC

Приобретения, слияния, поглощения

Australia's AUB Opens Books to EQT After Receiving $3.44 Billion Takeover Offer

27 окт. 2025 г., 21:42 UTC

Отчет

Waste Management 3Q Revenue Climbs, Sees Fiscal Year Revenue at Low End of Prior View

27 окт. 2025 г., 23:43 UTC

Обсуждения рынка

Nikkei May Rise on Easing U.S.-China Trade Tensions -- Market Talk

27 окт. 2025 г., 23:42 UTC

Обсуждения рынка

Gold Rises on Likely Technical Recovery -- Market Talk

27 окт. 2025 г., 23:37 UTC

Обсуждения рынка

Investors May Cheer CSL's Decision to Delay Seqirus Spinoff -- Market Talk

27 окт. 2025 г., 23:00 UTC

Отчет

The Good Vibes Are Back on Wall Street -- WSJ

27 окт. 2025 г., 22:45 UTC

Приобретения, слияния, поглощения

Australia's AUB Opens Books to EQT After Receiving $3.44B Takeover Offer

27 окт. 2025 г., 22:06 UTC

Обсуждения рынка
Отчет

Nucor Expects Weaker Steel Market in 4Q -- Market Talk

27 окт. 2025 г., 22:05 UTC

Отчет

China Southern Airlines: Continued Improvements in Business Environment Supported Results >1055.HK

27 окт. 2025 г., 22:04 UTC

Отчет

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 окт. 2025 г., 22:04 UTC

Отчет

China Southern Airlines 3Q Net CNY3.84B, Up 20.3% on Year >1055.HK

27 окт. 2025 г., 22:03 UTC

Отчет

China Southern Airlines 3Q Rev CNY51.37B, Up 3.0% on Year >1055.HK

27 окт. 2025 г., 21:27 UTC

Отчет

Waste Management 3Q Rev Climbs, Sees FY Rev at Low End of Prior View

27 окт. 2025 г., 21:19 UTC

Отчет

Cadence Reports Solid Earnings. The Stock Is Falling. -- Barrons.com

27 окт. 2025 г., 20:50 UTC

Обсуждения рынка
Приобретения, слияния, поглощения

Health Care Roundup: Market Talk

27 окт. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

27 окт. 2025 г., 20:37 UTC

Отчет

Waste Management: Decrease From Prior Rev Expectations Is Primarily Related to Further Decline in Recycled Commodity Pricing, Modestly Lower Rev Expectations From Healthcare Solutions >WM

27 окт. 2025 г., 20:37 UTC

Отчет

Waste Management: 2025 Free Cash Flow Guidance Remains Between $2.8B and $2.9B >WM

27 окт. 2025 г., 20:37 UTC

Отчет

Waste Management: 2025 Total Co Rev Is Now Expected Approximately $25.275B >WM

27 окт. 2025 г., 20:37 UTC

Отчет

Waste Management: Affirming 2025 Adjusted Operating EBITDA Guidance Between $7.475B and $7.625B >WM

27 окт. 2025 г., 20:31 UTC

Отчет

Nucor Sees 4Q Earnings Lower Than 3Q

27 окт. 2025 г., 20:30 UTC

Отчет

Nucor 3Q Steel Mills Total Shipments 6.43M Tons >NUE

27 окт. 2025 г., 20:30 UTC

Отчет

Nucor 3Q EPS $2.63 >NUE

27 окт. 2025 г., 20:30 UTC

Отчет

Nucor 3Q Net $607M >NUE

27 окт. 2025 г., 20:30 UTC

Отчет

Nucor 3Q Sales $8.52B >NUE

27 окт. 2025 г., 20:30 UTC

Отчет

Nucor 3Q Total Tons Shipped to Outside Customers Down 1% >NUE

27 окт. 2025 г., 20:30 UTC

Отчет

Waste Management 3Q Adj EPS $1.98 >WM

27 окт. 2025 г., 20:30 UTC

Отчет

Waste Management 3Q Rev $6.44B >WM

27 окт. 2025 г., 20:30 UTC

Отчет

Waste Management 3Q Net $603M >WM

Сравнение c конкурентами

Изменение цены

BioMarin Pharmaceutical Inc Прогноз

Целевая цена

By TipRanks

70.97% рост

Прогноз на 12 месяцев

Средняя 90.05 USD  70.97%

Максимум 120 USD

Минимум 55 USD

Основано на мнении 21 аналитиков Wall Street, спрогнозировавших целевые цены для BioMarin Pharmaceutical Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

21 ratings

17

Покупка

4

Удержание

0

Продажа

Техническая оценка

By Trading Central

59.405 / 62.19Поддержка и Сопротивление

Краткосрочная

Very Strong Bearish Evidence

Среднесрочная

Very Strong Bearish Evidence

Долгосрочная

Weak Bearish Evidence

Настроения

By Acuity

139 / 373Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании BioMarin Pharmaceutical Inc

BioMarin Pharmaceutical Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease. The company's commercial products also comprise Palynziq, a PEGylated recombinant phenylalanine ammonia lyase enzyme, which is delivered through subcutaneous injection to reduce blood Phe concentrations; Brineura, a recombinant human tripeptidyl peptidase 1 for the treatment of patients with ceroid lipofuscinosis type 2, a form of Batten disease; Voxzogo, a once daily injection analog of c-type natriuretic peptide for the treatment of achondroplasia; and Aldurazyme, a purified protein designed to be identical to a naturally occurring form of the human enzyme alpha-L-iduronidase. In addition, it develops Roctavian, an adeno associated virus vector, for the treatment of patients with severe hemophilia A. The company serves specialty pharmacies, hospitals, and non-U.S. government agencies, as well as distributors and pharmaceutical wholesalers in the United States, Europe, Latin America, and internationally. It has license and collaboration agreements with Sarepta Therapeutics; Ares Trading S.A.; Catalyst Pharmaceutical Partners, Inc.; and CAMP4 Therapeutics Corporation. The company was incorporated in 1996 and is headquartered in San Rafael, California.
help-icon Live chat